Sramila Aithal, MD, from Cancer Treatment Centers of America, discusses the HERceptin Adjuvant (HERA) trial that examined adjuvant therapy with trastuzumab for women with HER2-positive early breast cancer.
Sramila Aithal, MD
Advertisement
Articles by Sramila Aithal, MD
Advertisement
Latest Updated Articles
Dr. Aithal on the HERceptin Adjuvant (HERA) TrialPublished: October 25th 2012 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
Lurbinectedin-Based Triplet Shows Clinical Benefit in Advanced Soft Tissue Sarcoma
2
Ultra-Sensitive ctDNA and CSF Liquid Biopsy May Refine Monitoring and Adaptive Trial Designs in Metastatic Breast Cancer
3
Anti–Gremlin-1 Therapy Plus Chemo Makes Waves in GI Malignancies
4
FDA Approves Larger Vial Size for Nelarabine Injection in T-ALL and T-LBL
5